An ambispective, multicenter study for rechallenge of nivolumab in patients with metastatic renal cell carcinoma
Latest Information Update: 18 Mar 2021
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms RENIVO
- 18 Mar 2021 New trial record
- 13 Feb 2021 Results assessing efficacy and safety of rechallenge of nivolumab for treatment of metastatic renal cell carcinoma, presented at the 2021 Genitourinary Cancers Symposium